purchase ordinary shares of Modern Pharma Company Limited ("Modern") in the proportion of 100% of the total shares from the existing shareholders with details as follows: 1. D/M/Y of the transaction The
quarter of 2018 was decreased from 26% to 22%. This is because product/service cost mix changed, with the proportion of cost of non-mobile top-up service increasing. Expenses and expenses to revenues from
quarter of 2020 increased from 19% to 22% due to the proportion of revenue of a former large customer with a low gross margin tended to continually decline. Q1’ 2020 Q1’ 2019 Increase (decrease) Million
of 2017 amounted of Baht 140.0 million, decreased by 30.0% when compared to the third quarter of 2016, high proportion of loan loss reserves ratio at 184.32%. Earnings per share for the third quarter
) -0.04 -0.13 Gross Margin -2.21% -22.86% Net Profit Margin -22.07% -62.45% Debt to Equity Ratio (Time) 4.36 4.36 Total Expenses Financial Performance of 3rd quarter for 9 months ended September 30, 2017
accounts decreased by 39.5% due to the allowances for bad debt and doubtful accounts of the bank are adequate as seen from high proportion of loan loss reserves ratio is at 184.32%. Earnings per share for
42.4% 196.5 52.0% Gross Profit 685.9 64.5% 781.9 57.6% 96.0 14.0% Other Revenues 8.6 0.8% 5.4 0.4% -3.2 -36.8% Gain from Shareholding Proportion Change in Subsidiaries to Long term investment 143.9 13.5
to Equity Ratio (Time) 1.78 5.88 Total Expenses The 2017 Operating Result as ended 31 December 2017 General Information The Company’ s Board of Directors had passed its resolution to arrange the 1/2017
' performance in the past Q2/2020, many financial institutions have increased their NPL to total loan ratio. The company has a positive view of the situation in terms of purchasing additional non-performing debt